Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines (original) (raw)

• Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J et al. (2004). Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 66: 1397–1405.
  Article CAS Google Scholar
• Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y et al. (2006). ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 118: 483–489.
  Article CAS Google Scholar
• Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C et al. (2004). Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 24: 7469–7482.
  Article CAS Google Scholar
• Canaple L, Kakizawa T, Laudet V . (2003). The days and nights of cancer cells. Cancer Res 63: 7545–7552.
  CAS PubMed Google Scholar
• Chaney SG, Sancar A . (1996). DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88: 1346–1360.
  Article CAS Google Scholar
• Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D . (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929–937.
  CAS Google Scholar
• Deeley RG, Westlake C, Cole SP . (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849–899.
  Article CAS Google Scholar
• Dickinson DA, Forman HJ . (2002). Cellular glutathione and thiols metabolism. Biochem Pharmacol 64: 1019–1026.
  Article CAS Google Scholar
• Fawcett TW, Martindale JL, Guyton KZ, Hai T, Holbrook NJ . (1999). Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. Biochem J 339: 135–141.
  CAS PubMed PubMed Central Google Scholar
• Fojo T, Bates S . (2003). Strategies for reversing drug resistance. Oncogene 22: 7512–7523.
  Article CAS Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee C . (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111: 41–50.
  Article CAS Google Scholar
• Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M et al. (1994). Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85: 426–433.
  Article CAS Google Scholar
• Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP et al. (1998). Role of the Clock protein in the mammalian circadian mechanism. Science 280: 1564–1569.
  Article CAS Google Scholar
• Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS et al. (2005). Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the Clock/BMAL1 transactivation complex. Proc Natl Acad Sci USA 102: 3407–3412.
  Article CAS Google Scholar
• Gottesman MM, Fojo T, Bates SE . (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58.
  Article CAS Google Scholar
• Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M et al. (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11: 619–633.
  Article CAS Google Scholar
• Husain A, He G, Venkatraman ES, Spriggs DR . (1998). BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58: 1120–1123.
  CAS Google Scholar
• Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD et al. (1996). Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981–14988.
  Article CAS Google Scholar
• Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y et al. (2005). Transcription factors and drug resistance. Eur J Cancer 41: 2577–2586.
  Article CAS Google Scholar
• Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T et al. (2000). Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60: 1312–1316.
  CAS PubMed Google Scholar
• Krishnamurthy P, Schuetz JD . (2006). Role of abcg2/bcrp in biology and medicine. Annu Rev Pharmacol Toxicol 46: 381–410.
  Article CAS Google Scholar
• Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N et al. (1998). Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol 55: 605–615.
  Article CAS Google Scholar
• Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M et al. (1999). Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 262: 924–932.
  Article CAS Google Scholar
• Lai GM, Ozols RF, Young RC, Hamilton TC . (1989). Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 81: 535–539.
  Article CAS Google Scholar
• Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM . (2001). Posttranslational mechanisms regulate the mammalian circadian clock. Cell 107: 855–867.
  Article CAS Google Scholar
• Liebermann DA, Hoffman B . (2002). Myeloid differentiation (MyD)/growth arrest DNA damage (GADD) genes in tumor suppression, immunity and inflammation. Leukemia 16: 527–541.
  Article CAS Google Scholar
• Masuoka HC, Townes TM . (2002). Targeted disruption of the activating transcription factor 4 gene results in severe fetal anemia in mice. Blood 99: 736–745.
  Article CAS Google Scholar
• Moore RY . (1997). Circadian rhythms: basic neurobiology and clinical applications. Annu Rev Med 48: 253–266.
  Article CAS Google Scholar
• Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M et al. (2001). Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 93: 869–874.
  Article CAS Google Scholar
• Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y . (2002). Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 101: 488–495.
  Article CAS Google Scholar
• Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M et al. (1996). Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56: 4224–4228.
  CAS PubMed Google Scholar
• Renes J, de Vries EG, Jansen PL, Muller M . (2000). The (patho)physiological functions of the MRP family. Drug Resist Updat 3: 289–302.
  Article CAS Google Scholar
• Rutkowski DT, Kaufman RJ . (2003). All roads lead to ATF4. Dev Cell 4: 442–444.
  Article CAS Google Scholar
• Rutter J, Reick M, Wu LC, McKnight SL . (2001). Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293: 510–514.
  Article CAS Google Scholar
• Saburi Y, Nakagawa M, Ono M, Sakai M, Muramatsu M, Kohno K et al. (1989). Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res 49: 7020–7025.
  CAS PubMed Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM . (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234.
  Article CAS Google Scholar
• Takano H, Kohno K, Matsuo K, Matsuda T, Kuwano M . (1992). DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 3: 323–330.
  Article CAS Google Scholar
• Tanabe M, Izumi H, Ise T, Higuchi S, Yamori T, Yasumoto K et al. (2003). Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 63: 8592–8595.
  CAS PubMed Google Scholar
• Tew KD . (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313–4320.
  CAS PubMed Google Scholar
• Tipnis SR, Blake DG, Shepherd AG, McLellan LI . (1999). Overexpression of the regulatory subunit of gamma-glutamylcysteine synthetase in HeLa cells increases gamma-glutamylcysteine synthetase activity and confers drug resistance. Biochem J 337: 559–566.
  Article CAS Google Scholar
• Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T et al. (2005). Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5: 15–27.
  Article CAS Google Scholar
• Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M et al. (2002). p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694–31702.
  Article CAS Google Scholar
• Wang D, Lippard SJ . (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307–320.
  Article CAS Google Scholar
• Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T et al. (2004). ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin–Lowry Syndrome. Cell 117: 387–398.
  Article CAS Google Scholar
• Yao KS, Godwin AK, Johnson SW, Ozols RF, O’Dwyer PJ, Hamilton TC . (1995). Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367–4374.
  CAS PubMed Google Scholar
• Yoshida A, Takemura H, Inoue H, Miyashita T, Ueda T . (2006). Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway. Cancer Res 66: 5772–5780.
  Article CAS Google Scholar